Apotex Pharmaceuticals

Apotex is Canada's largest generic pharmaceutical company, providing a diverse range of high-quality, affordable prescription and non-prescription medicines. Founded in 1974 by Dr. Barry Sherman, the company began as a small operation in Toronto and rapidly expanded to become a global player in the healthcare industry. Today, it produces thousands of dosages across various therapeutic classes, including cardiovascular, central nervous system, and anti-infective treatments.

While its roots and primary operations remain in Canada, Apotex has a widespread global manufacturing presence. Its production facilities are located in Canada (with major sites in Toronto and Brantford), India, Mexico, and China. This multi-country manufacturing strategy allows the company to export medical products to over 115 countries worldwide.

In April 2023, Apotex transitioned from being a family-owned business to part of a private equity portfolio following its acquisition by SK Capital Partners, a New York-based firm specializing in the life sciences and specialty materials sectors. As of 2026, the company continues to expand its reach through strategic acquisitions, including the purchase of nutritional supplement and specialty healthcare firms, while maintaining its corporate headquarters in Toronto. There have been recent reports indicating the company may explore a potential public listing in the near future.